230 related articles for article (PubMed ID: 26098776)
21. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.
Cuenca A; Cheng F; Wang H; Brayer J; Horna P; Gu L; Bien H; Borrello IM; Levitsky HI; Sotomayor EM
Cancer Res; 2003 Dec; 63(24):9007-15. PubMed ID: 14695219
[TBL] [Abstract][Full Text] [Related]
22. Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis--implications for tumor tolerance.
Robinson BW; Scott BM; Lake RA; Stumbles PA; Nelson DJ; Fisher S; Marzo AL
Clin Cancer Res; 2001 Mar; 7(3 Suppl):811s-817s. PubMed ID: 11300477
[TBL] [Abstract][Full Text] [Related]
23. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration.
Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M
J Invest Dermatol; 2000 Dec; 115(6):1059-64. PubMed ID: 11121142
[TBL] [Abstract][Full Text] [Related]
24. Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process.
Preynat-Seauve O; Contassot E; Schuler P; Piguet V; French LE; Huard B
Cancer Res; 2007 May; 67(10):5009-16. PubMed ID: 17510433
[TBL] [Abstract][Full Text] [Related]
25. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
26. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
27. Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma.
Alb M; Sie C; Adam C; Chen S; Becker JC; Schrama D
Cancer Immunol Immunother; 2012 Dec; 61(12):2239-49. PubMed ID: 22674057
[TBL] [Abstract][Full Text] [Related]
28. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
29. Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells.
Kato Y; Yoshino I; Egusa C; Maeda T; Pili R; Tsuboi R
J Dermatol Sci; 2014 Aug; 75(2):140-7. PubMed ID: 24866536
[TBL] [Abstract][Full Text] [Related]
30. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.
Anichini A; Molla A; Vegetti C; Bersani I; Zappasodi R; Arienti F; Ravagnani F; Maurichi A; Patuzzo R; Santinami M; Pircher H; Di Nicola M; Mortarini R
Cancer Res; 2010 Nov; 70(21):8378-87. PubMed ID: 20861189
[TBL] [Abstract][Full Text] [Related]
31. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
32. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
33. Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes.
Hargadon KM; Brinkman CC; Sheasley-O'neill SL; Nichols LA; Bullock TN; Engelhard VH
J Immunol; 2006 Nov; 177(9):6081-90. PubMed ID: 17056534
[TBL] [Abstract][Full Text] [Related]
34. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes.
Arca MJ; Krauss JC; Strome SE; Cameron MJ; Chang AE
Cancer Immunol Immunother; 1996 May; 42(4):237-45. PubMed ID: 8665571
[TBL] [Abstract][Full Text] [Related]
35. ICAM-1-LFA-1 Dependent CD8+ T-Lymphocyte Aggregation in Tumor Tissue Prevents Recirculation to Draining Lymph Nodes.
Yanguas A; Garasa S; Teijeira Á; Aubá C; Melero I; Rouzaut A
Front Immunol; 2018; 9():2084. PubMed ID: 30258446
[TBL] [Abstract][Full Text] [Related]
36. CD8(+) T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysis.
Wang Q; Klinke DJ; Wang Z
BMC Syst Biol; 2015 Jun; 9():27. PubMed ID: 26048402
[TBL] [Abstract][Full Text] [Related]
37. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.
Kerkar SP; Goldszmid RS; Muranski P; Chinnasamy D; Yu Z; Reger RN; Leonardi AJ; Morgan RA; Wang E; Marincola FM; Trinchieri G; Rosenberg SA; Restifo NP
J Clin Invest; 2011 Dec; 121(12):4746-57. PubMed ID: 22056381
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells.
Stewart TJ; Smyth MJ; Fernando GJ; Frazer IH; Leggatt GR
Cancer Res; 2003 Jun; 63(12):3058-60. PubMed ID: 12810627
[TBL] [Abstract][Full Text] [Related]
39. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.
Lugade AA; Moran JP; Gerber SA; Rose RC; Frelinger JG; Lord EM
J Immunol; 2005 Jun; 174(12):7516-23. PubMed ID: 15944250
[TBL] [Abstract][Full Text] [Related]
40. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
